Illumina (ILMN) Receives Price Target

Illumina (ILMN) : Currently there are 10 street experts covering Illumina (ILMN) stock. The most bullish and bearish price target for the stock is $180 and $115 respectively for the short term. The average price target of all the analysts comes to $152.1. The estimated standard deviation from the target is $20.63.

Illumina (ILMN) : Zacks Investment Research ranks Illumina (ILMN) as 2, which is a Buy recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 10 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 15 research analysts is 2.55, which indicates as a Hold.


Also, In a research note released to the investors, CL King downgrades its rating on Illumina (NASDAQ:ILMN).The analysts at the brokerage house have a current rating of Neutral on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on August 22, 2016.

Illumina (NASDAQ:ILMN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $168.72 and $166.31 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $169.05. The buying momentum continued till the end and the stock did not give up its gains. It closed at $168.56, notching a gain of 0.13% for the day. The total traded volume was 562,774 . The stock had closed at $168.34 on the previous day.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *